MALARIA VACCINES MARKET ANALYSIS

Malaria vaccines are therapeutics that offer protection against mosquito-borne infectious disease called malaria. Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. Individuals who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. Although malaria can be a deadly disease, illness and death from malaria can usually be prevented.

Global Malaria Vaccines Market is estimated to be valued at US$ 41.08 million in 2022 and is expected to exhibit a CAGR of 29.6% during the forecast period (2022-2030).

Figure 1.Global Malaria Vaccines Market Share (%) in Terms of Value, By Agent, 2022

To learn more about this report, request sample copy

Increasing government initiatives for prevention of malaria are expected to drive market growth during the forecast period.

Increasing government initiatives for prevention of malaria are expected to drive the global malaria vaccines market growth over the forecast period. For instance, in October 2021, the World Health Organization (WHO) recommended widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. The recommendation was based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has reached more than 900 000 children since 2019.

Figure 2.Global Malaria Vaccines Market Share (%), By Vaccine Type, 2022

To learn more about this report, request sample copy

Rising inorganic strategies by key players for development of malaria vaccine are expected to drive the market growth during the forecast period

Rising inorganic strategies such as agreements by key players for development of malaria vaccine are expected to drive global malaria vaccines market growth during the forecast period. For instance, October 2021, Sanaria Inc., a biotechnology company and Seattle Children’s Research Institute, the US’s best children’s hospitals, announced the signing of an agreement to collaborate on development and commercialization of next generation PfSPZ vaccines attenuated by genetic engineering. Sanaria PfSPZ Vaccine and Sanaria PfSPZ-CVac vaccine have shown 100% protective efficacy against controlled human malaria infection with highly variant Pf parasites and importantly, protection against Pf infection in multiple trials in Africa

Global Malaria Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus or COVID-19 outbreak started from Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. Economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat spread of coronavirus since 2020. Furthermore, the COVID-19 pandemic is affecting malaria control efforts. For instance, according to data published in BioMed Central Ltd, a U. K.-based, for-profit scientific open access publisher in April 2020, due to the COVID-19 pandemic, a consortium established for testing malaria vaccines had joined to combat COVID-19, thus possibly decreasing their resources for malaria vaccines. External funds might be diverted for the same reason. Avoidance of health care facilities means a decrease of participants.

Global Malaria Vaccines Market: Restraint

The major factors that hinder growth of the global malaria vaccines market include barriers to developing a malaria vaccine. For instance, according to data published by Centers for Disease Control and Prevention in October 2021, development of a malaria vaccine has faced several obstacles: the lack of a traditional market, few developers, and the technical complexity of developing any vaccine against a parasite. Malaria parasites have a complex life cycle, and there is poor understanding of the complex immune response to malaria infection. Malaria parasites are also genetically complex, producing thousands of potential antigens. Unlike the diseases for which we currently have effective vaccines, exposure to malaria parasites does not confer lifelong protection.

Key Players

Key players operating in the market include GlaxoSmithKline, Nobelpharma, Sanaria, CellFree Sciences, VLP Therapeutics LLC, Sumaya Biotech, BioNTech, and Precigen, Inc.